Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.
about
BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade.Integrative analysis of transcriptomics and clinical data uncovers the tumor-suppressive activity of MITF in prostate cancer
P2860
Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Comparative oncogenomics ident ...... tumor suppressor in melanoma.
@en
type
label
Comparative oncogenomics ident ...... tumor suppressor in melanoma.
@en
prefLabel
Comparative oncogenomics ident ...... tumor suppressor in melanoma.
@en
P2093
P2860
P50
P356
P1476
Comparative oncogenomics ident ...... tumor suppressor in melanoma.
@en
P2093
Bram Boeckx
Corinna Köhler
Enrico Radaelli
Flavie Luciani
Florian Rambow
Joost J van den Oord
Julie C Tisserand
Michael Olvedy
Sophie Lopez
P2860
P304
P356
10.1172/JCI91291
P407
P50
P577
2017-05-02T00:00:00Z